Rahul D. Ballal, Director at Enliven Therapeutics, Inc. (ELVN), sold 6,474 shares at $19.08 ($124K) on 2024-04-01, disclosed to the SEC on 2024-04-03.
Scheduled sale ($124k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.08 | 3,237 | $62K | 50.0% |
| 2 | $19.08 | 3,237 | $62K | 50.0% |
| Total | $19.08 avg | 6,474 | $124K | 100% |
| Filing → |
| ELVN | SELL | 2024-04-12 | $1.6M | — | Filing → |
| ELVN | SELL | 2024-04-08 | $133K | — | Filing → |
| ELVN | SELL | 2024-03-22 | $509K | — | Filing → |